Tisagenlecleucel,axicabtagene ciloleucel
novartis ,daiichi sankyo,gilead
['lysa']
sibon - pmbcl prognostic factors
- 290 pts, 5 diff lysa trials
- 80 had autosct
- 4y pfs for racvbp/rchop-14/r-chop-21: 86%, 78%, 64%
- 4y os r-acvbp / -14 both better than -21
- mva: nccn-ipi and regimen were prog
- no benefit asct
intensity maybe important in pmbcl
#ash22 
Associate Professor of Haematology and lymphoma specialist at Oxford Cancer and Haematology centre. Christian, husband and father.